INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript

Daniel Carlson: Well, thanks guys. After going through COVID with a number of companies, missing their timelines because of enrolment issues, it’s great to see these trends. So thank you for that. Appreciate it.

Operator: Thank you. As there are no further questions, I would now hand the conference over to Dr. RJ Tesi for his closing comments.

RJ Tesi: Yeah. So thank you. So INmune Bio is making progress on two fronts and we’re pretty proud of that. I will say the drug development landscape for the treatment in cognitive decline in Alzheimer’s disease is really changing rapidly and we are impressed how quickly the conversation has pivoted from treatment of dementia to prevention of dementia and I can’t help wonder that this rapid pivot is because of the satisfaction and frustration of the — with the approved therapies. There’s still a niggling concern that the risk profile is not ideal, but I have to say at INmune Bio, we have a little bit of a different view. We believe the anti-amyloid drugs are chasing the wrong target. We believe neuroinflammation is intimately involved in disrupting nerve cell function and survival and synaptic function and those are the two central elements needed for cognitive decline.

With XPro, we are attacking this pathology and have strong evidence that we change the biology of the brain for the better. The ongoing Phase 2 trial will allow us to correlate these biologic benefits with cognitive change, and we hope cognitive benefits. Stay tuned because the positive result there opens the door to other indications where neuroinflammation meets cognitive dysfunction. Likewise, INKmune is an NK therapy of a different stripe. The biology is sound. It’s a lifetime of work by Mark Lowdell, and he is getting finally recognized for what has been long due. We marvel at the safety profile of this immunotherapy. Could this be a cancer therapy that really has no side effects and only has benefits? Time will tell, and we believe the metastatic castrate resistant prostate cancer trial will give the product and INKmune, a good chance to shine.

We remain optimistic about both our programs, and we thank you for your support and your attention.

Operator: Thank you. The conference of INmune Bio has now concluded. Thank you for your participation. You may now disconnect your lines.